Infusion 51a's Press Releases
Our Portfolio Companies' Press Releases
Infusion 51a attends its first event in Bahrain: the MENA Angel Investors Summit
From left to right: Mr. Nawaf Mohamed Alkoheji, Scott VanderMeer, Mehrab Ajalli and Mr. Mishari Yousef. Manama, Bahrain, November 14th, 2022 – Infusion 51a, an
Infusion 51a launched disruptive cancer awareness campaign with over 50 local students across the streets of Dubai
Based on the premise that “there is a person behind each diagnosis,” #FACESNOTNUMBERS is a campaign that seeks to humanize statistics by portraying the experiences
Infusion 51a Joins the Overseas Conversation in the EMERGE GHI and PrecisionMed events in Dubai
Infusion 51a LP (“Infusion 51a” or the “Fund”), an impact investment fund investing in life-science companies aiming to help patients around the world, participated in
Infusion 51a Sponsors the Champions for a Cure Tournament, an Event by To Cure a Rose Foundation
Pinehurst, North Carolina February 21st, 2022 – Infusion 51a LP (“Infusion 51a” or the “Fund”), an impact investment firm funding oncological companies to help millions
Infusion 51a and BioWise Capital make a splash in the 75th NYC PostGraduate Assembly in Anesthesiology
Chicago, IL. Dec 13, 2021. Infusion 51a and BioWise Capital brought their expertise together in partnership at the 75th PostGraduate Assembly in Anesthesiology (PGA), celebrated
Our Portfolio Companies' Press Releases
Our Portfolio Companies' Press Releases
Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory
Seasoned Cancer Research Fellow with specialized interest in Reverse Phase Protein Array Technology to bolster Theralink’s management team Golden, Colorado—November 7, 2022 — Theralink Technologies, Inc.
Vivacitas Oncology Presents for the Second Year in a row at the 2022 SAPA Conference
Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe,
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022
Dr. Volker W. Stieber, MD, Joins Vivacitas’ Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, February 7, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, is proud to present Dr. Volker